ALNYLAM PHARMACEUTICALS, INC. Deferred Tax Liabilities, Other Comprehensive Income
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Deferred Tax Liabilities, Other Comprehensive Income of $0 as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesOtherComprehensiveIncome · last filed 2026-02-12
- 2025-12-31: Deferred Tax Liabilities, Other Comprehensive Income $0.00.
- 2024-12-31: Deferred Tax Liabilities, Other Comprehensive Income $2.04M.
- 2023-12-31: Deferred Tax Liabilities, Other Comprehensive Income $2.28M.
- 2022-12-31: Deferred Tax Liabilities, Other Comprehensive Income $5.73M.
| Period end | Deferred Tax Liabilities, Other Comprehensive Income |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-12 |
| 2024-12-31 | $2.04M 10-K · filed 2026-02-12 |
| 2023-12-31 | $2.28M 10-K · filed 2025-02-13 |
| 2022-12-31 | $5.73M 10-K · filed 2024-02-15 |
| 2021-12-31 | $16.69M 10-K · filed 2023-02-23 |
| 2020-12-31 | $12.77M 10-K · filed 2022-02-10 |
| 2019-12-31 | $3.93M 10-K · filed 2021-02-11 |
| 2018-12-31 | $903.00K 10-K · filed 2020-02-13 |
| 2017-12-31 | $765.00K 10-K · filed 2019-02-14 |
| 2016-12-31 | $1.52M 10-K · filed 2018-02-15 |
| 2015-12-31 | $14.95M 10-K · filed 2017-02-15 |
| 2014-12-31 | $32.79M 10-K · filed 2016-02-12 |
| 2013-12-31 | $13.27M 10-K · filed 2015-02-13 |
| 2012-12-31 | $10.57M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |